JP2011502101A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502101A5
JP2011502101A5 JP2009530646A JP2009530646A JP2011502101A5 JP 2011502101 A5 JP2011502101 A5 JP 2011502101A5 JP 2009530646 A JP2009530646 A JP 2009530646A JP 2009530646 A JP2009530646 A JP 2009530646A JP 2011502101 A5 JP2011502101 A5 JP 2011502101A5
Authority
JP
Japan
Prior art keywords
composition
partial agonist
receptor partial
administered
adenosine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/079955 external-priority patent/WO2008042796A2/en
Publication of JP2011502101A publication Critical patent/JP2011502101A/ja
Publication of JP2011502101A5 publication Critical patent/JP2011502101A5/ja
Pending legal-status Critical Current

Links

JP2009530646A 2006-09-29 2007-09-28 肺疾患の病歴を有する患者における心筋画像化法 Pending JP2011502101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84829406P 2006-09-29 2006-09-29
US88971707P 2007-02-13 2007-02-13
PCT/US2007/079955 WO2008042796A2 (en) 2006-09-29 2007-09-28 Methods for myocardial imaging in patients having a history of pulmonary disease

Publications (2)

Publication Number Publication Date
JP2011502101A JP2011502101A (ja) 2011-01-20
JP2011502101A5 true JP2011502101A5 (cg-RX-API-DMAC7.html) 2011-10-13

Family

ID=39031215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530646A Pending JP2011502101A (ja) 2006-09-29 2007-09-28 肺疾患の病歴を有する患者における心筋画像化法

Country Status (5)

Country Link
US (1) US20080170990A1 (cg-RX-API-DMAC7.html)
EP (1) EP2066232A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011502101A (cg-RX-API-DMAC7.html)
CA (1) CA2663361A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008042796A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
KR20090047499A (ko) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) * 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) * 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5270304A (en) * 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
ATE127472T1 (de) * 1989-06-20 1995-09-15 Yamasa Shoyu Kk Zwischenverbindung für 2- alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2- alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
US5516894A (en) * 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
EP0601322A3 (en) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
ATE218139T1 (de) * 1994-02-23 2002-06-15 Kyowa Hakko Kogyo Kk Xanthin-derivate
US5704491A (en) * 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5854081A (en) * 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) * 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) * 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
AU2001238665A1 (en) * 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6387913B1 (en) * 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
AR035891A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de sulfonamida, un proceso para su produccion, su uso para la fabricacion de un medicamento para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada de activacion del receptor de bradiquinina beta1, y composiciones farmaceuticas y combinaci
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
PL370207A1 (en) * 2001-11-09 2005-05-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
EA007468B1 (ru) * 2001-12-20 2006-10-27 Оси Фармасьютикалз, Инк. Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
EP2311462A1 (en) * 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US20060159621A1 (en) * 2005-01-12 2006-07-20 Barrett Richard J Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm
PL1989214T3 (pl) * 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
WO2008063712A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
KR20090047499A (ko) * 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
MX2011003168A (es) * 2008-09-29 2011-05-19 Gilead Sciences Inc Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples.

Similar Documents

Publication Publication Date Title
JP2011502101A5 (cg-RX-API-DMAC7.html)
JP2010515081A5 (cg-RX-API-DMAC7.html)
JP2010502649A5 (cg-RX-API-DMAC7.html)
Maruyama et al. Myocardial injury in patients with chronic hepatitis C infection
Kaymakoglu et al. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients
Hamid Pathogenesis of small airways in asthma
Puckelwartz et al. Nesprin-1 mutations in human and murine cardiomyopathy
Sunagawa et al. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats
CA2662278A1 (en) Methods and compositions for increasing patient tolerability during myocardial imaging methods
JP2010515081A (ja) 心筋灌流画像化
Paiardi et al. Immunohistochemical evaluation of microvascular rarefaction in hypertensive humans and in spontaneously hypertensive rats
JP2005538190A5 (cg-RX-API-DMAC7.html)
US20150018299A1 (en) Treatment of liver conditions
Rajani et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion
JP2017536380A5 (cg-RX-API-DMAC7.html)
Kaski et al. Cardiac syndrome X: an overview
Satoh et al. Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation
Maas et al. Evidence that the acute phase of ischemic preconditioning does not require signaling by the A2B adenosine receptor
Warren et al. Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors
Feng et al. The role of hemodynamic and vasoactive substances on hepatopulmonary syndrome.
Ito Can measurement of chemokines become useful biological and functional markers of early-stage chronic pancreatitis?
Wahed et al. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy
Thackeray et al. Early diabetes treatment does not prevent sympathetic dysinnervation in the streptozotocin diabetic rat heart
Fallon et al. Hepatopulmonary syndrome
Emre et al. Effect of Hormone Replacement Therapy on Plasma Lipoproteins and Apolipoproteins, Endothelial Function and Myocardial Perfusion in Postmenopausal Women with Estrogen Receptor-α IVS1–397 C/C Genotype and Established Coronary Artery Disease